Table 1 Clinico-pathological data and distribution of scores in the entire cohort of patients
E-cadherin | Nuclear β-catenin | ||||||||
|---|---|---|---|---|---|---|---|---|---|
Factors | N (%) 98 (100) | Absent | Low | Mode-rate | High | Absent | Low | Mode-rate | High |
Sex | |||||||||
M | 72 (73%) | 1 (1%) | 2 (3%) | 13 (18%) | 56 (78%) | 30 (42%) | 26 (36%) | 12 (17%) | 4 (6%) |
F | 26 (27%) | 1 (4%) | 0 (0%) | 5 (19%) | 20 (77%) | 9 (35%) | 9 (35%) | 6 (23%) | 2 (8%) |
Age | |||||||||
</= 50 | 48 (49%) | 2 (2%) | 1 (1%) | 15 (18%) | 66 (77%) | 33 (39%) | 31 (37%) | 15 (18%) | 5 (6%) |
>50 | 50 (51%) | 0 (0%) | 1 (7%) | 3 (21%) | 10 (72%) | 6 (43%) | 4 (29%) | 3 (21%) | 1 (7%) |
Anal margin | |||||||||
<= 5 cm | 84 (86%) | 1 (2%) | 1 (2%) | 7 (15%) | 39 (81%) | 21 (44%) | 17 (35%) | 7 (15%) | 3 (6%) |
>5 cm | 4 (14%) | 1 (2%) | 1 (2%) | 11 (22%) | 37 (72%) | 18 (36%) | 18 (36%) | 11 (22%) | 3 (6%) |
T stage | |||||||||
T2-3 | 80 (82%) | 2 (3%) | 2 (3%) | 15 (19%) | 61 (85%) | 29 (36%) | 30 (37%) | 15 (19%) | 6 (8%) |
T4 | 18 (18%) | 0 (0%) | 0 (0%) | 3 (17%) | 15 (83%) | 10 (56%) | 5 (28%) | 3 (17%) | 0 (0%) |
N stage | |||||||||
N- | 43 (44%) | 0 (0%) | 1 (2%) | 7 (13%) | 44 (85%) | 21 (40%) | 16 (31%) | 12 (23%) | 3 (6%) |
N+ | 55 (56%) | 2 (4%) | 1 (2%) | 11 (24%) | 32 (70%) | 18 (39%) | 19 (41%) | 6 (13%) | 3 (7%) |
TGR* | |||||||||
TGR 1 | 17 (17%) | 0 (0%) | 1 (6%) | 3 (18%) | 13 (76%) | 5 (29%) | 9 (53%) | 2 (12%) | 1 (6%) |
TGR 2 | 27 (28%) | 1 (4%) | 0 (0%) | 3 (11%) | 23 (85%) | 7 (26%) | 11 (41%) | 7 (26%) | 2 (7%) |
TGR 3 | 23 (24%) | 1 (4%) | 1 (4%) | 2 (9%) | 19 (83%) | 11 (48%) | 6 (26%) | 4 (17%) | 2 (9%) |
TGR 4 | 26 (26%) | 0 (0%) | 0 (0%) | 8 (31%) | 18 (69%) | 14 (54%) | 7 (27%) | 4 (15%) | 1 (4%) |
TGR 5 | 5 (5%) | 0 (0%) | 0 (0%) | 2 (40%) | 3 (60%) | 8 (40%) | 2 (40%) | 1 (20%) | 0 (0%) |
pN †† | |||||||||
pN- | 70 (71%) | 2 (3%) | 1 (1%) | 13 (19%) | 54 (77%) | 27 (39%) | 26 (37%) | 12 (17%) | 5 (7%) |
pN+ | 28 (29%) | 0 (0%) | 1 (4%) | 5 (18%) | 22 (78%) | 12 (43%) | 9 (32%) | 6 (21%) | 1 (4%) |